This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3iu3
From Proteopedia
| Line 4: | Line 4: | ||
==Disease== | ==Disease== | ||
| - | [[http://www.uniprot.org/uniprot/IL2RA_HUMAN IL2RA_HUMAN]] Genetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:[http://omim.org/entry/601942 601942]]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:17676041</ref> | + | [[http://www.uniprot.org/uniprot/IL2RA_HUMAN IL2RA_HUMAN]] Genetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:[http://omim.org/entry/601942 601942]]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.<ref>PMID:17676041</ref> |
==Function== | ==Function== | ||
| Line 10: | Line 10: | ||
==About this Structure== | ==About this Structure== | ||
| - | [[3iu3]] is a 9 chain structure with sequence from [http://en.wikipedia.org/wiki/ | + | [[3iu3]] is a 9 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3IU3 OCA]. |
==See Also== | ==See Also== | ||
| Line 18: | Line 18: | ||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID:020032294</ref><references group="xtra"/><references/> | <ref group="xtra">PMID:020032294</ref><references group="xtra"/><references/> | ||
| - | [[Category: | + | [[Category: Human]] |
[[Category: Ding, J.]] | [[Category: Ding, J.]] | ||
[[Category: Du, J.]] | [[Category: Du, J.]] | ||
Revision as of 09:34, 5 February 2014
Contents |
Crystal structure of the Fab fragment of therapeutic antibody Basiliximab in complex with IL-2Ra (CD25) ectodomain
Template:ABSTRACT PUBMED 20032294
Disease
[IL2RA_HUMAN] Genetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:601942]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.[1]
Function
[IL2RA_HUMAN] Receptor for interleukin-2.
About this Structure
3iu3 is a 9 chain structure with sequence from [1] and Human. Full crystallographic information is available from OCA.
See Also
Reference
- Du J, Yang H, Zhang D, Wang J, Guo H, Peng B, Guo Y, Ding J. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol. 2010 Feb 1;184(3):1361-8. Epub 2009 Dec 23. PMID:20032294 doi:10.4049/jimmunol.0903178
- ↑ Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007 Sep;39(9):1074-82. Epub 2007 Aug 5. PMID:17676041 doi:10.1038/ng2102
Categories: Human | Ding, J. | Du, J. | Wang, J. | Yang, H. | Basiliximab | Cd25 | Disulfide bond | Glycoprotein | Il-2ra | Immune system | Membrane | Receptor | Simulect | Sushi | Therapeutic antibody | Transmembrane
